Navigation Links
Wound Management Technologies Announces Clinical Study Presentation of CellerateRx(R) Technology at Leading Skin and Wound Care Conference
Date:10/16/2009

FORT WORTH, Texas, Oct. 16 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today that its subsidiary Wound Care Innovations, LLC will exhibit at the 24th Annual Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing, which opens on October 22 in San Antonio.

Dr. Jane Fore MD, FAPWCA, FACCWS, medical director of the Tri-State Wound Care and Hyperbaric Center in Clarkston, WA, will present the results of her clinical study that showed that the use of hydrolyzed collagen (CellerateRx) increased the efficiency of healing in skin tears/flaps. Most were resolved within one week with a single application. Her abstract is entitled, "Activated Collagen: An Evidence Based Skin Tear Study."

Over 1100 multidisciplinary practitioners--nurses, physicians, podiatrists, physical therapists, dieticians, and others who manage skin and wound care patients across the continuum of health care are expected to attend. The conference will provide continuing-education needs of multidisciplinary skin and wound care practitioners, from novice to expert, with educational sessions and interactive workshops that offer comprehensive wound management strategies.

Dr. Fore said, "I am delighted to be presenting this abstract on the use of CellerateRx on skin tears and flaps. I have been using CellerateRx in my wound care protocols for over five years. It is an essential part of my successful wound care treatments. More of the regional nursing homes in my area are taking my skin tear protocol (CellerateRx) and are adapting it into their facilities due to the outcomes and cost effectiveness."

Cathy Bradshaw, president of Wound Care Innovations, said, "Skin tears represent a major problem in the elderly and compromised patients. Untreated skin tears can serve as a portal of entry for infection and be a source of pain for the patient. Their treatment can also have an impact on facilities' resources. This evidence based abstract demonstrates that the use of CellerateRx is not only effective in the management of skin tears, but also very cost effective as well, as shown by resolution with only one application."

CellerateRx is FDA cleared for use on acute and chronic wounds which includes but is not limited to pressure ulcers (stages I-IV), traumatic wounds, diabetic ulcers, surgical wounds, venous stasis ulcers, ulcers due to arterial insufficiency, superficial wounds, and first and second degree burns.

For more information about Wound Care Innovations go to www.celleraterx.com

About Wound Management Technologies, Inc.:

Wound Management Technologies, through its subsidiary Wound Care Innovations, markets and distributes wound care products to the healthcare market under patented technology licensed to the company. The company is positioned and seeks to be a leading provider of wound care products. The company's corporate headquarters are in Fort Worth, Texas. For more information please visit the company's website at www.celleraterx.com.

An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors may be found at www.hawkassociates.com.

A profile for investors can be accessed at http://www.hawkassociates.com/clients/profile/wnmd.cfm.

To receive free e-mail notification of future releases for Wound Management Technologies, sign up at www.hawkassociates.com/about/alert/.

Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

    Contacts:
    Product information, contact Cathy Bradshaw at 954-315-9242.
    Shareholder relations, contact Lucy Singleton at 817-820-7080.
    Investor relations information, contact Frank Hawkins or Julie Marshall,
    Hawk Associates, at 305-451-1888 or email woundcare@hawkassociates.com.

SOURCE Wound Management Technologies, Inc.


'/>"/>
SOURCE Wound Management Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015
2. Reportlinker Adds Wound Care Markets, 4th. Edition, Vol. II: Burns Report
3. ULURU Inc. Presents Results of First Randomized Clinical Trial for Altrazeal(TM) at the Symposium on Advanced Wound Care (SAWC) Fall Meeting in Washington D.C.
4. A Solution for Successful Wound Management: B. Braun Announces Prontosan(R) Availability at Symposium for Advanced Wound Care (SAWC) Fall Event
5. Karolinska Development Introduces New Concept for Development of its Dermatology and Wound Healing Portfolio
6. Reportlinker Adds Markets for Advanced Wound Care Technologies Report
7. Join The Wound, Ostomy & Continence Nurses Society As It Makes History
8. Wounded Warrior Project to Participate in BGC Partners Annual Charity Day
9. Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States
10. A Wound that Does Not Heal: Frost & Sullivan Reveals the Impact of Chronic Ulcers on the European Healthcare System
11. Chairman of the Joint Chiefs of Staff to Discuss Wounded Warrior Issues at the USNI & MOAA 2009 Defense Forum Washington
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... , ... February 13, 2016 , ... Hidden Cypress in Sun City is the place ... facial plastic surgery. Dr. Frederick Weniger will be hosting this educational seminar from ... event, and there will be special pricing on offers. In addition, prizes will be given ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... The producers ... impact of American businesses. , The increasingly modern world of instantaneous consumption proves ... on non-renewable energy sources such as oil and coal, which pollutes our air, water, ...
(Date:2/13/2016)... ... 13, 2016 , ... DDi , a Makro company, ... for its expertise in eClinical Solutions. DDi has built its solution competency with ... of global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Coco Libre, the ... in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians ... stay hydrated before the big event. The invitation-only gifting suite, held this year at ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
Breaking Medicine Technology: